TY - JOUR T1 - Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination JF - medRxiv DO - 10.1101/2021.07.12.21260227 SP - 2021.07.12.21260227 AU - Anastasia A. Minervina AU - Mikhail V. Pogorelyy AU - Allison M. Kirk AU - E. Kaitlynn Allen AU - Kim J. Allison AU - Chun-Yang Lin AU - David C. Brice AU - Xun Zhu AU - Kasi Vegesana AU - Gang Wu AU - Jeremy Chase Crawford AU - Stacey Schultz-Cherry AU - Jeremie H. Estepp AU - Maureen A. McGargill AU - the SJTRC Study Team AU - Joshua Wolf AU - Paul G. Thomas Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/27/2021.07.12.21260227.abstract N2 - SARS-CoV-2 mRNA vaccines, including Pfizer/Biontech BNT162b2, were shown to be effective for COVID-19 prevention, eliciting both robust antibody responses in naive individuals and boosting pre-existing antibody levels in SARS-CoV-2-recovered individuals. However, the magnitude, repertoire, and phenotype of epitope-specific T cell responses to this vaccine, and the effect of vaccination on pre-existing T cell memory in SARS-CoV-2 convalescent patients, are still poorly understood. Thus, in this study we compared epitope-specific T cells elicited after natural SARS-CoV-2 infection, and vaccination of both naive and recovered individuals. We collected peripheral blood mononuclear cells before and after BNT162b2 vaccination and used pools of 18 DNA-barcoded MHC-class I multimers, combined with scRNAseq and scTCRseq, to characterize T cell responses to several immunodominant epitopes, including a spike-derived epitope cross-reactive to common cold coronaviruses. Comparing responses after infection or vaccination, we found that T cells responding to spike-derived epitopes show similar magnitudes of response, memory phenotypes, TCR repertoire diversity, and αβTCR sequence motifs, demonstrating the potency of this vaccination platform. Importantly, in COVID-19-recovered individuals receiving the vaccine, pre-existing spike-specific memory cells showed both clonal expansion and a phenotypic shift towards more differentiated CCR7-CD45RA+ effector cells. In-depth analysis of T cell receptor repertoires demonstrates that both vaccination and infection elicit largely identical repertoires as measured by dominant TCR motifs and receptor breadth, indicating that BNT162b2 vaccination largely recapitulates T cell generation by infection for all critical parameters. Thus, BNT162b2 vaccination elicits potent spike-specific T cell responses in naive individuals and also triggers the recall T cell response in previously infected individuals, further boosting spike-specific responses but altering their differentiation state. Overall, our study demonstrates the potential of mRNA vaccines to induce, maintain, and shape T cell memory through vaccination and revaccination.Competing Interest StatementP.G.T has consulted or received honorarium and travel support from Illumina and 10X. P.G.T. serves on the Scientific Advisory Board of Immunoscape and Cytoagents.Funding StatementThis work was funded by ALSAC at St. Jude, the Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP) contract number 75N93019C00052 (S.S-C, P.G.T), the St. Jude Center of Excellence for Influenza Research and Surveillance (S.S-C, M.A.M, P.G.T), HHSN272201400006C, 3U01AI144616-02S1 (P.G.T, M.A.M, S.S-C), and R01AI136514 (P.G.T).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The St. Jude Institutional Review Board approved of this study on April 20, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode required to reproduce source data for figures is available on GitHub: https://github.com/pogorely/COVID_vax_CD8. All data produced in the study is available as supplementary files. Raw sequencing data was deposited to Short Read Archive acc. PRJNA744851. ER -